Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11529305 | 0.97 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL27311624 | 0.97 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL28257054 | 0.97 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL26697594 | 0.97 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL10412274 | 0.97 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL26697631 | 0.97 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL26697578 | 0.97 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL10835848 | 0.97 | TSHR (0.60) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL27278949 | 0.94 | SMN1; SMN2 (0.67) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| SCHEMBL8434344 | 0.92 | TSHR (0.68) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024019936-A1 | NANOMATERIALS COMPRISING TRIOLS | BEAM THERAPEUTICS INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-117320710-A | Combination therapy for fumarate-related diseases | 易姆赛斯股份公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4281050-A1 | NANOMATERIALS | Beam Therapeutics Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-116761888-A | Nanomaterial for the preparation of a nanoparticle | 比姆医疗股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230172894-A1 | COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES | IMCYSE SA (BE) | 2023-06-08 | — | — | US | disclosed |
| EP-4146190-A2 | COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES | Imcyse SA (BE) | 2023-03-15 | — | — | EP | disclosed |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2021144478-A2 | COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES | IMCYSE SA (BE) | 2021-07-22 | — | — | WO | disclosed |
| CN-112741811-A | Novel continuous controllable drug delivery system for central nervous system drugs | 江苏集萃新型药物制剂技术研究所有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10994003-B2 | Dimethyl fumarate and vaccination regimens | BIOGEN MA INC. (US) | 2021-05-04 | — | — | US | disclosed |
| CN-102427727-A | Treatment of neurodegeneration and neuroinflammation | BIOGEN IDEC INC | 2012-04-25 | — | — | CN | disclosed |
| EP-2424357-A1 | TREATMENT OF NEURODEGENERATION AND NEUROINFLAMMATION | Biogen Idec MA Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011100589-A1 | NEUROPROTECTION IN DEMYELINATING DISEASES | BIOGEN IDEC MA INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2010126605-A1 | TREATMENT OF NEURODEGENERATION AND NEUROINFLAMMATION | BIOGEN IDEC MA INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100130607-A1 | NEUROPROTECTION IN DEMYELINATING DISEASES | BIOGEN MA INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2139467-A2 | NEUROPROTECTION IN DEMYELINATING DISEASES | Gold, Ralf (DE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008096271-A2 | NEUROPROTECTION IN DEMYELINATING DISEASES | GOLD RALF (DE) | 2008-08-14 | — | — | WO | disclosed |
| CN-101132781-A | Room-temperature stable dronabinol formulations | INSYS THERAPEUTICS INC (US) | 2008-02-27 | — | — | CN | disclosed |
| CN-101091019-A | Patterned application of activated carbon ink | KIMBERLY CLARK CO (US) | 2007-12-19 | — | — | CN | disclosed |
| CN-1658861-A | Novel formate salt of o-desmethyl-venlafaxine | WYETH CORP (US) | 2005-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172894-A1 | COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES | FH, HLA-DRB1, HLA-B | SMN1; SMN2 2452/4885TSHR 4621/4885LMNA 4179/4885 |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | SMN1; SMN2 640/4885TSHR 4093/4885LMNA 4083/4885 |
| US-10994003-B2 | Dimethyl fumarate and vaccination regimens | FH, HLA-DRB1, SDHB | SMN1; SMN2 640/4885TSHR 4093/4885LMNA 4083/4885 |
| US-20100130607-A1 | NEUROPROTECTION IN DEMYELINATING DISEASES | PMP22, TFB2M, SMN1; SMN2 | SMN1; SMN2 3/4885TSHR 4173/4885LMNA 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.